EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Kinetics of serum O‐glycosylated M‐hepatitis B surface antigen with hepatocellular carcinoma history and nucleos(t)ide analogue therapy in hepatitis B patients

Taiki Okumura, Satoru Joshita iD, Takanobu Iwadare, Shun-Ichi Wakabayashi, Hiroyuki Kobayashi, Yuki Yamashita, Ayumi Sugiura, Takefumi Kimura, Takeji Umemura iD

Journal of Viral Hepatitis · 2023-09 · 30 (9) · 731-739

DOI: 10.1111/jvh.13869 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Viral Hepatitis, online erschienen am 26.06.2023. Verfasst von Taiki Okumura und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Gastroenterology and Hepatology, Shinshu University School of Medicine, Matsumoto, Japan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Hepatitis B, Chronic, Liver Neoplasms, Hepatitis B. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A newly developed O‐glycosylated M‐hepatitis B surface antigen (HBsAgGi) measurement system can detect hepatitis B surface antigen (HBsAg) associated with infectious particles. We investigated the association of HBsAgGi levels with clinical parameters and a history of hepatocellular carcinoma (HCC) development in a cross‐sectional cohort analysis (Study 1) as well as the quantitative changes in HBsAgGi during nucleos(t)ide analogue (NA) therapy in a longitudinal cohort analysis (Study 2). A total of 124 patients with genotype C chronic HBV infection were analysed in Study 1 to evaluate correlations of HBsAgGi with conventional HBV markers and HCC history. Among those, 36 patients receiving NA therapy were enrolled in Study 2 for quantitative comparisons between pre‐treatment baseline and 48 weeks of NA therapy. In Study 1, serum HBsAgGi was significantly associated with HBsAg ( r = .5857, p < .00001) and weakly but significantly correlated with HBV DNA ( r = .2936, p = .001). Although HBsAgGi ( p = .111) was comparable between HCC history (+) group and HCC history (−) group, the HBsAgGi/HBsAg ratio ( p = .011) was significantly higher in HCC history (+) patients. In Study 2, HBsAgGi was significantly decreased after 48 weeks of NA therapy ( p < .001). HBsAg findings were similar ( p = .005) along with an HBV DNA reduction ( p < .001). In the baseline hepatitis B e antigen (HBeAg) (+) subgroup, HBsAgGi decreased significantly between baseline and 48 weeks of NA ( p = .005), while HBsAg was comparable ( p = .051). Low HBsAg and high HBsAgGi were associated with a history of HCC development. HBsAgGi decreased significantly by 48‐week NA therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularHepatitis B, ChronicLiver NeoplasmsHepatitis BHumansHepatitis B Surface AntigensAntiviral AgentsDNA, ViralKineticsCross-Sectional StudiesHepatitis B virusHepatitis B e Antigens

Stichwörter der Autor:innen

O-glycosylationhepatitis B surface antigenhepatitis B virusnucleos(t)ide analogue

Substanzen

Hepatitis B Surface AntigensAntiviral AgentsDNA, ViralHepatitis B e Antigens

Autor:innen und Institutionen

  • Department of Medicine, Division of Gastroenterology and Hepatology, Shinshu University School of Medicine, Matsumoto, Japan.
  • Department of Health Promotion Medicine, Shinshu University School of Medicine, Matsumoto, Japan.
  • Department of Advanced Endoscopic Therapy, Shinshu University School of Medicine, Matsumoto, Japan.
  • Consultation Center for Liver Diseases, Shinshu University Hospital, Matsumoto, Japan.

ORCID-Profile: Satoru Joshita, Takeji Umemura

Förderung

  • Japan Agency for Medical Research and Development

Zitieren

APA

Okumura, T., Joshita, S., Iwadare, T., Wakabayashi, S. I., Kobayashi, H., Yamashita, Y., Sugiura, A., Kimura, T., & Umemura, T. (2023). Kinetics of serum O‐glycosylated M‐hepatitis B surface antigen with hepatocellular carcinoma history and nucleos(t)ide analogue therapy in hepatitis B patients. Journal of Viral Hepatitis, 30(9), 731-739. https://doi.org/10.1111/jvh.13869

Vancouver

Okumura T, Joshita S, Iwadare T, Wakabayashi SI, Kobayashi H, Yamashita Y, et al. Kinetics of serum O‐glycosylated M‐hepatitis B surface antigen with hepatocellular carcinoma history and nucleos(t)ide analogue therapy in hepatitis B patients. Journal of Viral Hepatitis. 2023;30(9):731-739. doi:10.1111/jvh.13869

BibTeX
@article{Okumura2023,
  author = {Okumura, Taiki and Joshita, Satoru and Iwadare, Takanobu and Wakabayashi, Shun-Ichi and Kobayashi, Hiroyuki and Yamashita, Yuki and Sugiura, Ayumi and Kimura, Takefumi and Umemura, Takeji},
  title = {Kinetics of serum O‐glycosylated M‐hepatitis B surface antigen with hepatocellular carcinoma history and nucleos(t)ide analogue therapy in hepatitis B patients},
  journal = {Journal of Viral Hepatitis},
  year = {2023},
  volume = {30},
  number = {9},
  pages = {731--739},
  doi = {10.1111/jvh.13869}
}
Kostenlos starten →